Valsartan Almus 320 mg film-coated tablets EFG

Package Leaflet: Information for the User

Introduction

Package leaflet: information for the user

Valsartán Almus 320 mg film-coated tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it could harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents:

1. What Valsartán Almus is and what it is used for
2. What you need to know before taking Valsartán Almus
3. How to take Valsartán Almus
4. Possible adverse effects
5. How to store Valsartán Almus
6. Contents of the pack and other information

1. What Valsartán Almus is and what it is used for

Valsartan belongs to a class of medicines known as angiotensin II receptor antagonists, which help control high blood pressure. Angiotensin II is a substance in the body that causes blood vessels to narrow, resulting in increased blood pressure. Valsartan works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.

Valsartán Almus can be used

• to treat high blood pressure in adults and in children and adolescents aged 6 to 18 years. High blood pressure increases the workload on the heart and arteries. If left untreated, it can damage the blood vessels of the brain, heart, and kidneys, and may lead to stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering blood pressure to normal levels reduces the risk of developing these conditions.

2. What you need to know before taking Valsartán Almus

Do not take Valsartán Almus:

• if you are allergic to valsartan or to any of the other ingredients of this medicine (listed in section 6),
• if you have severe liver disease,
• if you are more than 3 months pregnant (it is also advisable to avoid this medicine during the first months of pregnancy – see Pregnancy section),
• if you have diabetes or kidney failure and are being treated with a blood pressure-lowering medicine containing aliskiren.

If any of the above situations apply to you, inform your doctor and do not take Valsartán Almus.

Warnings and precautions

Talk to your doctor:

• if you have liver disease,

• if you have severe kidney disease or are undergoing dialysis,

• if you have narrowing of the artery supplying the kidney (renal artery stenosis),

• if you have recently undergone a kidney transplant (received a new kidney),

• if you are being treated for heart attack or heart failure, your doctor may monitor your kidney function,

• if you have a serious heart condition other than heart failure or heart attack,

• if you have previously experienced swelling of the tongue and face due to an allergic reaction called angioedema while taking other medicines (including ACE inhibitors), inform your doctor. If you develop these symptoms while taking Valsartán Almus, stop treatment immediately and do not take it again. See also section 4, "Possible side effects".

• if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Valsartán Almus. Your doctor will decide whether to continue treatment. Do not stop taking Valsartán Almus on your own.

• if you are taking medicines that increase blood potassium levels. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines, and heparin. Regular monitoring of blood potassium levels may be necessary,

• if you have aldosteronism, a condition in which the adrenal glands produce too much aldosterone hormone. In this case, taking Valsartán is not recommended,

• if you have lost a significant amount of fluid (dehydration) due to diarrhea, vomiting, or high doses of diuretics (medicines that increase urine output),

• if you are taking any of the following medicines used to treat high blood pressure (hypertension):

  • an angiotensin-converting enzyme inhibitor (ACE inhibitor) (e.g., enalapril, lisinopril, ramipril), particularly if you have kidney problems related to diabetes.
  • aliskiren

Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.

See also the information under the heading “Do not take Valsartán Almus”.

You must inform your doctor if you think you are (or may become) pregnant. Valsartán Almus is not recommended at the beginning of pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used during this period (see Pregnancy section).

Taking Valsartán Almus with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

The effect of treatment with Valsartán may be altered when taken together with certain medicines. Your doctor may need to adjust your dose and/or take other precautions, or in some cases, discontinue treatment with one of the medicines. This applies to both prescription and over-the-counter medicines, especially:

• other medicines that lower blood pressure, particularly diuretics (medicines that increase urine output), angiotensin-converting enzyme inhibitors (ACE inhibitors) (such as enalapril, lisinopril, etc.), or aliskiren (see also information under the headings “Do not take Valsartán Almus” and “Warnings and precautions”).

• medicines that increase blood potassium levels. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines, and heparin,

• certain medicines used to treat pain known as non-steroidal anti-inflammatory drugs (NSAIDs),

• some antibiotics (rifampicin group), a medicine used to prevent transplant rejection (cyclosporine), or an antiretroviral medicine used to treat HIV/AIDS infection (ritonavir). These medicines may increase the effect of Valsartán Almus.

• lithium, a medicine used to treat certain psychiatric conditions.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

• Inform your doctor if you are pregnant (or suspect you might be). Your doctor will generally advise you to stop taking valsartan before becoming pregnant or as soon as pregnancy is detected, and will recommend an alternative antihypertensive medicine. Valsartán Almus is not recommended during early pregnancy and must not be used from the third month of pregnancy onwards, as it may cause severe harm to your baby when used from this stage.

• Inform your doctor if you are planning to breastfeed or are currently breastfeeding, as Valsartán Almus is not recommended for women during this period. Your doctor may decide to prescribe a more suitable treatment if you wish to breastfeed, especially if your baby is a newborn or premature.

Driving and using machines

Before driving, operating tools, handling machinery, or engaging in other activities requiring concentration, make sure you know how Valsartán Almus affects you. Like many other medicines used to treat high blood pressure, Valsartán Almus may rarely cause dizziness and affect your ability to concentrate.

3. How to take Valsartán Almus

Follow exactly the instructions for use of this medicine given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

People with high blood pressure often do not experience any symptoms of the disease and frequently feel perfectly well. This makes it very important to keep your medical appointments, even if you feel fine.

Adult patients with high blood pressure: the recommended dose is 80 mg once daily. In some cases, your doctor may prescribe higher doses (e.g. 160 mg or 320 mg). Valsartán Almus may also be combined with another medicine (e.g. a diuretic).

Use in children and adolescents (6 to 18 years of age) with high blood pressure:

In patients weighing less than 35 kg, the recommended dose is 40 mg of valsartan once daily. In patients weighing 35 kg or more, the recommended starting dose is 80 mg of valsartan once daily. In some cases, your doctor may prescribe higher doses (the dose may be increased to 160 mg and up to a maximum of 320 mg).

Valsartán Almus may be taken with or without food. Swallow the tablet with a glass of water.

Take Valsartán Almus at approximately the same time each day.

If you take more Valsartán Almus than you should

If you experience severe dizziness and/or fainting, contact your doctor immediately and lie down. If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital. You may also call the Toxicology Information Service at telephone number 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Valsartán Almus

If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose.

Do not take a double dose to make up for a missed dose.

If you stop taking Valsartán

If you discontinue treatment with Valsartán Almus, your condition may worsen. Do not stop taking the medicine unless instructed by your doctor.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone experiences them.

Some adverse effects may be serious and may require immediate medical attention:

You may experience symptoms of angioedema (a specific allergic reaction), such as:

• swelling of the face, lips, tongue, or pharynx
• difficulty breathing or swallowing
• hives and itching

If you experience any of these symptoms, stop taking Valsartán Almus immediately and contact your doctor right away (see also section 2 “Warnings and precautions”).

Other adverse effects include:

Common (may affect up to 1 in 10 patients ):

• dizziness
• low blood pressure, with or without symptoms such as dizziness and fainting upon standing
• reduced kidney function (signs of renal impairment)

Uncommon (may affect up to 1 in 100 patients ):

• angioedema (see section “Some symptoms require immediate medical attention”)
• sudden loss of consciousness (syncope)
• sensation of spinning (vertigo)
• marked reduction in kidney function (signs of acute renal failure)
• muscle spasms, irregular heartbeat (signs of hyperkalemia)
• shortness of breath, difficulty breathing when lying down, swelling of the feet or legs (signs of heart failure)
• headache
• cough
• abdominal pain
• nausea
• diarrhea
• fatigue
• weakness

Rare (may affect up to 1 in 10,000 patients ):

• intestinal angioedema: swelling in the intestine causing symptoms such as abdominal pain, nausea, vomiting, and diarrhea

Frequency not known (frequency cannot be estimated from the available data ):

• skin blisters (sign of bullous dermatitis)
• allergic reactions may occur, with skin rash, itching, and hives; symptoms of fever, joint swelling and pain, muscle pain, swollen lymph nodes, and/or flu-like symptoms (signs of serum sickness)
• purplish red spots, fever, itching (signs of blood vessel inflammation, also called vasculitis)
• bleeding or bruising more easily than usual (signs of thrombocytopenia)
• muscle pain (myalgia)
• fever, sore throat, or mouth ulcers due to infections (symptoms of low white blood cell count, also called neutropenia)
• reduction in hemoglobin levels and reduced percentage of red blood cells in the blood (which, in severe cases, may lead to anemia)
• increased potassium levels in the blood (which, in severe cases, may cause muscle spasms and irregular heartbeat)
• elevation of liver function test values (which may indicate liver injury), including increased blood bilirubin levels (which, in severe cases, may cause yellowing of the skin and eyes)
• increased blood urea nitrogen and increased serum creatinine levels (which may indicate kidney function abnormalities)
• low sodium levels in the blood (which, in severe cases, may cause fatigue, confusion, muscle fasciculations, and/or seizures)

The frequency of some adverse effects may vary depending on your condition. For example, certain adverse effects such as dizziness and reduced kidney function were observed less frequently in patients treated for hypertension than in patients treated for heart failure or after a recent heart attack.

Side effects in children and adolescents are similar to those observed in adults.

Reporting of adverse effects

If you experience any type of adverse effect, talk to your doctor, pharmacist, or nurse, even if it is an effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: Website: www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Valsartán Almus

Keep this medicine out of sight and reach of children.

Do not store above 30°C. Keep in the original packaging.

Do not use Valsartán Almus after the expiry date stated on the packaging following EXP. The expiry date refers to the last day of the month indicated.

Do not use Valsartán if you notice that the packaging is damaged or shows signs of deterioration.

Medicines must not be disposed of via wastewater or household waste. Return any unused medicines and their packaging to the SIGRE point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of unused medicines and their packaging. This way, you will help protect the environment.

6. Contents of the pack and other information

Composition of Valsartán Almus

• The active substance is valsartan. Each tablet contains 320 mg of valsartan.
• The other components (excipients) are, in the core: microcrystalline cellulose, crospovidone, and magnesium stearate. The tablet coating contains hypromellose, titanium dioxide (E171), Macrogol PEG 8000, red iron oxide (E172), yellow iron oxide (E172), and black iron oxide (E172).

Nature of the product and pack sizes

Valsartán 320 mg film-coated tablets are brown, oblong, convex, film-coated tablets, scored on one side. The score is intended to facilitate breaking the tablet to aid swallowing, but not for dividing into equal doses. It is available in packs of 28 tablets.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Almus Farmacéutica, S.A.U.
Marie Curie, 54
08840 Viladecans (Barcelona), Spain
Telephone: 93 739 71 80
Email: [email protected]

Manufacturer:

Atlantic Pharma – Produções Farmacêuticas, S.A.
Rua De Tapada Grande 2
Abrunheira, Sintra, 2710 – 228
Portugal

Laboratorios Lesvi, S.L.
Avda. Barcelona, 69. 08970 Sant Joan Despí (Barcelona)
Spain

Date of the most recent review of this Patient Information Leaflet: March 2025

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.